

MEDIA & INVESTOR RELEASE

Novartis receives positive CHMP opinion for Pluvicto[®] for patients with progressive, PSMA-positive metastatic castration-resistant prostate cancer

- *Phase III VISION trial showed Pluvicto[®] plus best standard of care significantly improved survival for patients with pre-treated PSMA-positive mCRPC¹*
- *Approximately 473,000 prostate cancer cases and 108,000 prostate cancer-related deaths occurred across Europe in 2020²; Metastatic prostate cancer has a 5-year survival rate of approximately 30%³*
- *Two Phase III trials are underway to evaluate Pluvicto[®] for treatment in earlier stages of metastatic prostate cancer*

Basel, October 14, 2022 — Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting a marketing authorization for Pluvicto[®] (INN: lutetium (¹⁷⁷Lu) vipivotide tetraxetan) (formerly referred to as ¹⁷⁷Lu-PSMA-617), a radioligand therapy, in combination with androgen deprivation therapy (ADT) with or without androgen receptor (AR) pathway inhibition, for the treatment of adult patients with progressive prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with AR pathway inhibition and taxane based chemotherapy.

“People at this advanced stage of disease have already received many different treatments and have few alternatives left,” said Prof. Karim Fizazi, MD, PhD, VISION trial investigator and Head of Medical Oncology at Gustave Roussy, first European cancer center based in Villejuif, France. “If approved in Europe, Pluvicto[®] would represent a new type of precision medicine targeting a biomarker broadly expressed in prostate cancer patients⁴ and provide a therapeutic option with demonstrated potential to improve outcomes¹. As a clinician this gives me hope for patients facing a very difficult situation.”

The positive CHMP opinion is based on data from the Phase III VISION study, in which Pluvicto[®] plus best standard of care (BSoC) demonstrated significantly improved overall survival in PSMA-positive mCRPC patients previously treated with AR pathway inhibition and taxane-based chemotherapy compared to BSoC alone¹.

Results from the VISION trial demonstrated that participants treated with Pluvicto[®] plus BSoC had a 38% reduction in risk of death and a 60% reduction in the risk of radiographic disease progression or death (rPFS) compared to BSoC alone¹. In addition, approximately a third (29.8%) of patients with evaluable disease at baseline demonstrated an overall response (per RECIST 1.1) with Pluvicto[®] plus BSoC, compared to 1.7% in the BSoC alone arm¹. The most common adverse events (all grades) in the Pluvicto[®] arm of the study were fatigue (43%), dry mouth (39%), nausea (35%), anemia (low red blood cell counts) (32%), decreased appetite (21%), and constipation (20%)¹.

“This positive CHMP opinion for Pluvicto® is an important step forward in our goal of bringing transformative innovation to more patients around the world,” said Marie-France Tschudin, President, Innovative Medicines International & Chief Commercial Officer, Novartis. “If approved by the European Commission, Pluvicto® would be the first and only commercial radioligand therapy for people with advanced prostate cancer in Europe. We are committed to exploring the potential of radioligand therapy to address unmet needs in prostate cancer, including in earlier stages of disease.”

The CHMP’s positive opinion on Pluvicto® in PSMA–positive mCRPC patients will be referred to the European Commission (EC), which will deliver a final decision in approximately two months. The decision will be applicable to all 27 EU member states plus Iceland, Norway, Northern Ireland and Liechtenstein.

About Pluvicto® (lutetium (¹⁷⁷Lu) vipivotide tetraxetan)

Despite advances in prostate cancer care, there is a high unmet need for new targeted treatment options to improve outcomes for patients with mCRPC¹. Pluvicto® is a radioligand therapy combining a targeting compound (ligand, in this case directed to PSMA) with a therapeutic radioisotope (a radioactive particle, in this case lutetium-177)¹. Pluvicto® delivers radiation to PSMA-positive cells and the surrounding microenvironment¹. Pluvicto® was approved by the FDA in March 2022.

Two additional Phase III trials in earlier lines of treatment for metastatic prostate cancer are ongoing, investigating potential clinical utility in the mCRPC pre-taxane setting ([PSMAfore](#))¹¹ and in the metastatic hormone-sensitive setting ([PSMAddition](#))¹². Novartis is also evaluating opportunities to investigate Pluvicto® radioligand therapy in earlier stages of prostate cancer.

About VISION

VISION is an international, prospective, randomized, open-label, multicenter, phase III study that assessed the efficacy and safety of Pluvicto® (lutetium (¹⁷⁷Lu) vipivotide tetraxetan) (7.4 GBq administered by IV infusion every 6 weeks for a maximum of 6 cycles) plus investigator-chosen standard of care (BSoC) in the investigational arm, versus BSoC in the control arm¹. Patients with PSMA PET-scan positive mCRPC who have received androgen receptor (AR) pathway inhibition and taxane-based chemotherapy, were randomized in a 2:1 ratio in favor of the investigational arm¹. The alternate primary endpoints were rPFS and OS¹. The study enrolled 831 patients¹.

Novartis and Prostate Cancer

With more 1.4 million new cases and 375,000 deaths in 2020 alone, prostate cancer is the most frequently diagnosed cancer in 112 countries—more than half the world¹³.

At Novartis, we are harnessing the innovation of our world-class scientists, strategic partnerships, and one of the industry’s most competitive pipelines to explore the potential of new, targeted therapies and precision medicine platforms to address the greatest unmet needs in prostate cancer.

Through the bold science of targeted therapies, our goal is to reduce the global disease burden, extend the lives of patients with prostate cancer, and elevate current standards of care.

About Phenotypic Precision Medicine in advanced prostate cancer

More than 80% of patients with prostate cancer highly express a phenotypic biomarker⁴ called prostate-specific membrane antigen (PSMA)⁴⁻⁸, making it a promising diagnostic (through positron emission tomography (PET) scan imaging) and therapeutic target for radioligand therapy⁹. This differs from ‘genotypic’ precision medicine which targets specific genetic alterations in cancer cells¹⁰.

Disclaimer

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “seek,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis

Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 108,000 people of more than 140 nationalities work at Novartis around the world. Find out more at <https://www.novartis.com>.

Novartis is on Twitter. Sign up to follow @Novartis at <https://twitter.com/novartisnews>
For Novartis multimedia content, please visit <https://www.novartis.com/news/media-library>
For questions about the site or required registration, please contact media.relations@novartis.com

References

1. Sartor O, J. de Bono KN, Chi K, et al. Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. *NEJM* 2021; doi: 10.1056/NEJMoa2107322.
2. World Health Organization (WHO). (2022) *Cancer population fact sheet: Europe*. Retrieved from <https://gco.iarc.fr/today/data/factsheets/populations/908-europe-fact-sheets.pdf>
3. SEER. Cancer stat facts: prostate cancer April 2021. [<https://seer.cancer.gov/statfacts/html/prost.html>]
4. Hope TA, Aggarwal R, Chee B, et al. Impact of 68Ga-PSMA-11 PET on management in patients with biochemically recurrent prostate cancer. *J Nucl Med* 2017;58(12):1956–61
5. Hupe MC, Philippi C, Roth D, et al. Expression of prostate-specific membrane antigen (PSMA) on biopsies is an independent risk stratifier of prostate cancer patients at time of initial diagnosis. *Front Oncol* 2018;8:623.
6. Bostwick DG, Pacelli A, Blute M, et al. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. *Cancer* 1998;82(11):2256–61

7. Pomykala KL, Czernin J, Grogan TR, et al. Total-body 68Ga-PSMA-11 PET/CT for bone metastasis detection in prostate cancer patients: potential impact on bone scan guidelines. *J Nucl Med* 2020;61(3):405–11
8. Minner S, Wittmer C, Graefen M, et al. High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer. *Prostate* 2011;71(3):281–8
9. Hofman MS, Violet J, Hicks RJ et al. [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2.
10. Sant GR, Knopf KB, Albala DM. Live-single-cell phenotypic cancer biomarkers-future role in precision oncology? *NPJ Precision Oncology* 2017;1(1):21
11. Novartis Pharmaceuticals. 177Lu-PSMA-617 vs. Androgen Receptor-directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer (PSMAfore). U.S. National Library of Medicine: Clinical Trials. 2020; NCT04689828.
12. Novartis Pharmaceuticals. An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Soc, Versus SoC Alone, in Adult Male Patients With mHSPC (PSMAAddition). U.S. National Library of Medicine: Clinical Trials. 2021; NCT04720157.
13. Sung H, Ferlay J, Siegel RL, Sung H, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin.* 2021;71(3):209-249. doi:10.3322/caac.21660.

###

Novartis Media Relations

E-mail: media.relations@novartis.com

Anja von Treskow
 Novartis External Communications
 +41 79 392 8697 (mobile)
anja.von_treskow@novartis.com

Fran Rodrigues
 Novartis Innovative Medicines
 International Communications
 +41 79 413 4942
fran.rodrigues@novartis.com

Julie Masow
 Novartis US External Communications
 +1 862 579 8456 (mobile)
julie.masow@novartis.com

Novartis Investor Relations

Central investor relations line: +41 61 324 7944

E-mail: investor.relations@novartis.com

Central		North America	
Samir Shah	+41 61 324 7944	Sloan Simpson	+1 862 345 4440
Nicole Zinsli-Somm	+41 61 324 3809	Alina Levchuk	+1 862 778 3372
Isabella Zinck	+41 61 324 7188	Parag Mahanti	+1 973 876 4912